Clinical Trials Logo
  1. Home
  2. Glomerulonephritis
  3. NCT00437463

Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor

Glomerulonephritis Clinical Trial

Official title:
Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial

Clinical Trial Summary

To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00437463
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 3
Start date July 2004
Completion date September 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT00001457 - Lamivudine for Chronic Hepatitis B Phase 2
Recruiting NCT05505955 - Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency Phase 1
Recruiting NCT01240564 - The Nephrotic Syndrome Study Network (NEPTUNE) N/A
Active, not recruiting NCT05174221 - A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy Phase 1
Completed NCT00426348 - A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Phase 4
Recruiting NCT04662723 - Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Phase 4
Completed NCT02700516 - Recurrent Glomerulonephritis After Renal Transplantation N/A
Recruiting NCT00862693 - Calcitriol in the Treatment of Immunoglobulin A Nephropathy Phase 4
Completed NCT00983034 - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy N/A
Completed NCT00004990 - Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis Phase 2
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2
Terminated NCT04387448 - A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease Phase 2
Terminated NCT04950114 - An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases Phase 2
Terminated NCT02523768 - Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Phase 4
Completed NCT00106561 - Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney Phase 2/Phase 3
Completed NCT04733040 - Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE) Phase 2
Completed NCT00001676 - Cyclophosphamide and Fludarabine to Treat Lupus Nephritis Phase 1
Recruiting NCT02063100 - Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis Phase 4
Completed NCT01093157 - A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy Phase 1/Phase 2
Completed NCT05283057 - Empagliflozin in Patients With Glomerulonephritis Phase 3